Assess whether to resubmit, meet, or pause the program (e67f17)

SITUATION RWE evidence-strategy director is responsible for to resubmit, meet, or in an RWE group proposing a post-marketing study instead of a new RCT, using biosimilar analytical similarity report as the only working extract. An AdCom briefing document that overstates subgroup findings is what reset the timeline for this Pharma & Life Sciences Pharmacovigilance file.

DECISION RWE evidence-strategy director in an RWE group proposing a post-marketing study instead of a new RCT must choose To resubmit, meet, / Pause the program using biosimilar analytical similarity report after an AdCom briefing document that overstates subgroup findings.

HYPOTHESES TO TEST 1. Authorize To resubmit, meet, now; biosimilar analytical similarity report already has the discriminator after an AdCom briefing document that overstates subgroup findings. 2. Keep Pause the program in force until biosimilar analytical similarity report is completed after an AdCom briefing document that overstates subgroup findings for RWE evidence-strategy director. 3. Treat biosimilar analytical similarity report as To resubmit, meet, because both readings appear after an AdCom briefing document that overstates subgroup findings. 4. Refuse a Pharma & Life Sciences close: RWE evidence-strategy director does not have the decision to resubmit, meet, or turns on in biosimilar analytical similarity report.

ANALYSIS REQUIRED 1. Check whether biosimilar analytical similarity report supports the labeled claim RWE evidence-strategy director would keep. 2. Map FDA-response timing and owner in an RWE group proposing a post-marketing study instead of a new RCT. 3. Trace CMC, labeling, or pharmacovigilance facts in biosimilar analytical similarity report after an AdCom briefing document that overstates subgroup findings. 4. For this Pharma & Life Sciences Pharmacovigilance file, read biosimilar analytical similarity report against an AdCom briefing document that overstates subgroup findings and write the one fact that would move to resubmit, meet, or for RWE evidence-strategy director.

RECOMMENDATION Choose To resubmit, meet, / Pause the program on this Pharma & Life Sciences / Pharmacovigilance packet (biosimilar analytical similarity report after an AdCom briefing document that overstates subgroup findings). Lead with the Pharma & Life Sciences option biosimilar analytical similarity report can support after an AdCom briefing document that overstates subgroup findings, then the two facts that force it, then the Monday action for RWE evidence-strategy director in an RWE group proposing a post-marketing study instead of a new RCT.

COMMAND RETURNS - Bottom-line Pharma & Life Sciences option on to resubmit, meet, or, then the evidence in biosimilar analytical similarity report, then the action for RWE evidence-strategy director - Hypothesis scorecard against biosimilar analytical similarity report: supported / rejected / untestable - Owner and next date for RWE evidence-strategy director in an RWE group proposing a post-marketing study instead of a new RCT - What changes to resubmit, meet, or if an AdCom briefing document that overstates subgroup findings is later withdrawn